Pharmaceutical company payments to physicians: Early experiences with disclosure laws in Vermont and Minnesota

JAMA

Volumn 297, Issue 11, 2007, Pages 1216-1223

  Ross, Joseph S ^a,b,d   Lackner, Josh E ^c   Lurie, Peter ^c   Gross, Cary P ^d   Wolfe, Sidney ^c   Krumholz, Harlan M ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Public Citizen   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA ANALYSIS; DRUG INDUSTRY; HEALTH CARE PERSONNEL; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; LAW; MEDICAL FEE; ORGANIZATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; STATISTICAL ANALYSIS; UNITED STATES; GIFT GIVING; LEGAL ASPECT; PHYSICIAN; PUBLIC RELATIONS;

DISCLOSURE; DRUG INDUSTRY; GIFT GIVING; INTERPROFESSIONAL RELATIONS; MINNESOTA; PHYSICIANS; VERMONT;

EID: 33947521422     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.11.1216     Document Type: Article

References (23)

1. American Medical Association. Opinion E-8.061, gifts to physicians from industry. http://www.ama-assn.org/ama/pub/category/4001.html. Accessed January 31, 2007.
2. Coyle SL. Physician-industry relations, part 1: individual physicians. Ann Intern Med. 2002;136:396-402.
3. Canadian Medical Association. Physicians and the pharmaceutical industry (update 2001). CMAJ. 2001;164:1339-1344.
4. Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals, revised January 2004. http://www.phrma.org/files/PhRMA%20Code.pdf. Accessed January 31, 2007.
5. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-433.
6. Kassirer JP. On the Take: How America's Complicity With Big Business Can Endanger Your Health. New York, NY: Oxford University Press; 2004.
7. National Conference of State Legislatures. Marketing and direct-to-consumer advertising (DTCA) of pharmaceuticals, June 2, 2006. http://www.ncsl.org/programs/health/rxads.htm. Accessed January 31, 2007.
8. National Conference of State Legislatures. 2006 Prescription drug state legislation, November 6, 2006. http://www.ncsl.org/programs/health/drugbill06. htm. Accessed January 31, 2007.
9. State of Vermont. Vermont statutes online: Title 33, human services, chapter 19, medical assistance, 33 VSA § 2005: pharmaceutical marketers, January 2006. http://www.leg.state.vt.us/statutes/fullsection.cfm?Title= 33&Chapter=019&Section=02005. Accessed January 31, 2007.
10. State of Minnesota. Minnesota statutes: health, chapter 151, pharmacy, 151.47 wholesale drug distributor licensing requirements, January 2006. http://www.revisor.leg.state.mn.us/data/revisor/statutes/2005/151/47.html. Accessed January 31, 2007.
11. State of Minnesota. Minnesota statutes: health, chapter 151, pharmacy, 151.461 gifts to practitioners prohibited, January 2006. http://www.revisor.leg. state.mn.us/data/revisor/statutes/2005/151/461.html. Accessed January 31, 2007.
12. Minnesota Board of Medical Practice. Health professional database, November 2006. http://www.docboard.org/mn/df/mndf.htm. Accessed January 31, 2007.
13. Vermont Department of Health; Agency of Human Services. Docfinder downloadable databases, November 2006. http://www.healthvermont.gov/hc/ med_board/docfinder.aspx. Accessed January 31, 2007.
14. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
15. State of Vermont; Office of the Attorney General. Pharmaceutical marketing disclosures: report of Vermont Attorney General William H. Sorrell, February 25, 2004. http://www.atg.state.vt.us/upload/ 1077728093_Pharmaceutical_Marketing_Disclosures_Report.pdf. Accessed January 31, 2007.
16. State of Vermont; Office of the Attorney General. Pharmaceutical marketing disclosures: report of Vermont Attorney General William H. Sorrell, May 10, 2005. http://www.atg.state.vt.us/upload/ 1119349220_Pharmaceutical_Marketing_Disclosures_-
17. Freedom of Information Act, 5 USC §552 (2002).
18. Randall T. Kennedy hearings say no more free lunch - or much else - from drug firms. JAMA. 1991;265:440, 442.
19. Pharmaceutical Research and Manufacturers of America. Pharmaceutical marketing and promotion: tough questions, straight answers. http://www.phrma. org/files/Tough_Questions.pdf. Accessed January 31, 2007.
20. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990;5:240-243.
21. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26:1183-1189.
22. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-689.
23. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551-557.